Key facts
- This page summarizes Eric Warren's Form 3 filing for Esperion Therapeutics, Inc. (ESPR).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Mar 2022, 15:53.
Eric Warren - 01 Mar 2022 Form 3 Insider Report for Esperion Therapeutics, Inc. (ESPR)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- ESPR
- Reported as of
- 01 Mar 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 09 Mar 2022, 15:53:48 UTC
- Next SEC filing
- 16 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard B. Bartram, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Warren filed Form 3 for Esperion Therapeutics, Inc. (ESPR) on 09 Mar 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ESPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,207
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
ESPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,899
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F2
ESPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,000
- Date
- 01 Mar 2022
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These shares were acquired pursuant to a restricted stock unit award under the 2017 Inducement Equity Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of February 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date.
Footnote F2
These shares were acquired pursuant to a restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of July 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date.
Footnote F3
These shares were acquired pursuant to a performance-based restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each performance-based restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label.